Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2026—The CAP recently reached a record high of over 20,000 members, strengthening its advocacy efforts. Through PathPAC, the CAP engages with federal policymakers to advocate for pathologists and patient care. The CAP also advocates for the pathology community through its involvement with the AMA.
May 2026—Use of AI to define spatial patterns of tumor-infiltrating lymphocytes associated with patient outcome; Expanding the clinicopathologic spectrum of EWSR1::SSX-rearranged sarcomas
May 2026—Training in cell and gene therapy manufacturing via graduate medical education; Phase one trial of CRISPR-Cas9 gene editing targeting ANGPTL3
May 2026—Role of genetics and environment in shaping the human immune cell epigenome; Update on MRD in acute myeloid leukemia: a consensus document
May 2026
Q. When we receive new immunohistochemistry antibodies or DAB kits, they undergo a quality control process. Every institution where I have worked has done this task a little differently. When a laboratory receives a new antibody, what is the correct QC process? What if we receive two units of the same antibody from the same lot but one came in on Thursday and one on Friday? Read answer.
May 2026—The Centers for Medicare and Medicaid Services has issued a final rule that establishes HIPAA standards for electronic health care claims attachments.
May 2026—Barriers are preventing international medical graduates—students, residents, fellows, researchers, and practicing physicians—from entering the U.S. or remaining in the U.S. lawfully to continue their training or practice.
May 2026—I was a microbiology laboratory technologist before going to medical school and becoming a pathologist. At that time (many years ago), the taxonomists decided to split the genus Pasteurella into two genera of Pasteurella and Yersinia.
April 2026—It’s hard to mount an argument against the Great Plains. Nor is there much reason to. But drive across eastern Colorado, Nebraska, Kansas, or the Dakotas, and it is a bona fide thrill to arrive in Wyoming’s northwest corner and see the Grand Tetons rising up in spectacular fashion.
April 2026—Artificial intelligence, circulating tumor DNA, trial data: ASCO 2026 next month in Chicago will feature platforms, technologies, and therapeutic approaches once considered future concepts in cancer diagnosis and care. What comes now is less flashy than a breakthrough advance perhaps, but no less significant. As Janice Lu, MD, PhD, puts it, “The real work now is disciplined clinical translation: validation, collaboration, and implementation, in ways that truly improve patient care.”
